{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"71.6","value":"20.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Objective response was defined as the percentage of participants with a BOR of CR or PR by investigator assessment per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.","id":"OG000","title":"INCB099280 400 mg BID Plus Axitinib 5 mg BID"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set. Confidence intervals were calculated using the Clopper-Pearson method.","reportingStatus":"POSTED","timeFrame":"up to 335 days","title":"Part 1: Objective Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}